Cannabics Pharmaceuticals Inc (OTCQB: CNBX), a company involved in personalised cannabinoid based cancer medicine, announced yesterday that it has named Itamar Borochov as its new director and member of its board.
Borochov is an environmentalist with vast experience as an entrepreneur in the medical cannabis field, with broad experience in management and finance in medical cannabis companies that operate in regulated markets. He was the original founder of Cannabics Pharmaceuticals Inc.
Eyal Barad, CEO and co-founder, said, 'The entire team is pleased to have Itamar return to the board at a very significant time, and I am sure his intimate knowledge and industry experience will significantly contribute to the company as we move into our next planned phases.'
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
Celltrion USA launches denosumab biosimilars STOBOCLO and OSENVELT (denosumab-bmwo) in US
HotSpot Therapeutics presents small molecule CBM signalosome inhibitor program data
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
INOVIO prices USD25m public offering
Biocon Biologics' Denosumab biosimilars receive European Commission approval